Glen Eagle Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $157K | Hold |
1,001
| – | – | 0.02% | 299 |
|
|
2026
Q1 | $153K | Hold |
1,001
| – | – | 0.02% | 291 |
|
|
2025
Q4 | $138K | Sell |
1,001
-8
| -0.8% | -$1.05K | 0.02% | 297 |
|
|
2025
Q3 | $129K | Hold |
1,009
| – | – | 0.02% | 302 |
|
|
2025
Q2 | $122K | Sell |
1,009
-9
| -0.9% | -$1.01K | 0.02% | 295 |
|
|
2025
Q1 | $113K | Sell |
1,018
-22
| -2% | -$2.34K | 0.02% | 297 |
|
|
2024
Q4 | $101K | Hold |
1,040
| – | – | 0.02% | 305 |
|
|
2024
Q3 | $120K | Hold |
1,040
| – | – | 0.02% | 296 |
|
|
2024
Q2 | $111K | Hold |
1,040
| – | – | 0.02% | 291 |
|
|
2024
Q1 | $101K | Buy |
1,040
+50
| +5% | +$5.13K | 0.02% | 306 |
|
|
2023
Q4 | $100K | Buy |
990
+712
| +256% | +$68.7K | 0.02% | 296 |
|
|
2023
Q3 | $28.4K | Sell |
278
-1
| -0.4% | -$102 | 0.01% | 464 |
|
|
2023
Q2 | $28.1K | Buy |
279
+1
| +0.4% | +$100 | 0.01% | 469 |
|
|
2023
Q1 | $25.6K | Sell |
278
-75
| -21% | -$6.55K | 0.01% | 470 |
|
|
2022
Q4 | $32.1K | Hold |
353
| – | – | 0.01% | 418 |
|
|
2022
Q3 | $26.9K | Hold |
353
| – | – | 0.01% | 440 |
|
|
2022
Q2 | $29.9K | Hold |
353
| – | – | 0.01% | 436 |
|
|
2022
Q1 | $31K | Hold |
353
| – | – | 0.01% | 448 |
|
|
2021
Q4 | $30.9K | Sell |
353
-100
| -22% | -$8.3K | 0.01% | 444 |
|
|
2021
Q3 | $37.1K | Hold |
453
| – | – | 0.01% | 427 |
|
|
2021
Q2 | $41.4K | Buy |
453
+30
| +7% | +$2.67K | 0.01% | 412 |
|
|
2021
Q1 | $36.2K | Hold |
423
| – | – | 0.01% | 400 |
|
|
2020
Q4 | $40K | Buy |
423
+23
| +6% | +$2.01K | 0.02% | 362 |
|
|
2020
Q3 | $34.8K | Hold |
400
| – | – | 0.02% | 357 |
|
|
2020
Q2 | $35K | Buy |
400
+70
| +21% | +$6.04K | 0.02% | 341 |
|
|
2020
Q1 | $27.2K | Hold |
330
| – | – | 0.02% | 351 |
|
|
2019
Q4 | $31.3K | Buy |
330
+33
| +11% | +$2.96K | 0.02% | 391 |
|
|
2019
Q3 | $25.8K | Hold |
297
| – | – | 0.02% | 377 |
|
|
2019
Q2 | $27.1K | Sell |
297
-34
| -10% | -$2.88K | 0.02% | 361 |
|
|
2019
Q1 | $28.6K | Buy |
331
+83
| +33% | +$6.66K | 0.02% | 333 |
|
|
2018
Q4 | $19.1K | Hold |
248
| – | – | 0.02% | 369 |
|
|
2018
Q3 | $19.1K | Buy |
248
+25
| +11% | +$1.85K | 0.01% | 383 |
|
|
2018
Q2 | $15.1K | Hold |
223
| – | – | 0.01% | 399 |
|
|
2018
Q1 | $16.2K | Hold |
223
| – | – | 0.01% | 367 |
|
|
2017
Q4 | $16.8K | Hold |
223
| – | – | 0.01% | 362 |
|
|
2017
Q3 | $17.2K | Sell |
223
-223
| -50% | -$16.8K | 0.02% | 357 |
|
|
2017
Q2 | $33.4K | Hold |
446
| – | – | 0.03% | 251 |
|
|
2017
Q1 | $29.9K | Hold |
446
| – | – | 0.03% | 250 |
|
|
2016
Q4 | $29.1K | Buy |
+446
| New | +$28.9K | 0.03% | 247 |
|
Other funds holding NVS
Glen Eagle Advisors's NVS Position: Q2 2026 in Review
Glen Eagle Advisors held its Novartis (NVS) position steady in Q2 2026 at 1,001 shares worth $157K. The position accounts for 0.02% of the portfolio, ranked #299.
Glen Eagle Advisors first reported a position in NVS in Q4 2016 and has held it in 39 quarters since. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Glen Eagle Advisors held 1,001 shares of Novartis worth $157K as of Q2 2026.
- Glen Eagle Advisors left its Novartis share count unchanged in Q2 2026.
- Novartis made up 0.02% of Glen Eagle Advisors's portfolio in Q2 2026, its #299 holding.
- Glen Eagle Advisors first reported a position in Novartis in Q4 2016 and has held it in 39 quarters since.
- 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.